Skip to main content
Terug
BDX logo

Becton, Dickinson and Company

Datakwaliteit: 100%
BDX
NYSE Healthcare Medical - Instruments & Supplies
€ 156,23
▲ € 2,10 (1,36%)
Marktkapitalisatie: 56,60B
Dagbereik
€ 155,67 € 158,10
52-Weeksbereik
€ 127,59 € 187,35
Volume
1.652.406
50D / 200D Gem.
€ 166,77 / € 151,59
Vorige Slotkoers
€ 154,13

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 33,7 0,4
P/B 2,2 2,9
ROE % 6,5 3,8
Net Margin % 7,7 3,9
Rev Growth 5Y % 3,4 10,0
D/E 0,8 0,2

Koersdoel Analisten

Hold
€ 193,80 +24.0%
Low: € 170,00 High: € 215,00
Forward K/W
12,5
Forward WPA
€ 12,52
WPA Groei (sch.)
+0,0%
Omzet Sch.
19 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 16,91
€ 16,75 – € 17,26
22 B 1
FY2029 € 15,63
€ 15,48 – € 15,95
21 B 1
FY2028 € 14,29
€ 14,16 – € 14,59
20 B 1

Belangrijkste Punten

Revenue grew 3,37% annually over 5 years — modest growth
Generating 2,67B in free cash flow
P/E of 33,73 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,86%
Cash machine — converts 159,12% of earnings into free cash flow
Capital efficient — spends only 3,48% of revenue on capex

Groei

Revenue Growth (5Y)
3,37%
Revenue (1Y)8,23%
Earnings (1Y)-1,58%
FCF Growth (3Y)12,36%

Kwaliteit

Return on Equity
6,54%
ROIC4,34%
Net Margin7,68%
Op. Margin11,80%

Veiligheid

Debt / Equity
0,76
Current Ratio1,11
Interest Coverage4,21

Waardering

P/E Ratio
33,73
P/B Ratio2,23
EV/EBITDA29,07
Dividend Yield0,04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,23% Revenue Growth (3Y) 6,18%
Earnings Growth (1Y) -1,58% Earnings Growth (3Y) 6,34%
Revenue Growth (5Y) 3,37% Earnings Growth (5Y) -5,36%
Profitability
Revenue (TTM) 21,84B Net Income (TTM) 1,68B
ROE 6,54% ROA 3,03%
Gross Margin 45,44% Operating Margin 11,80%
Net Margin 7,68% Free Cash Flow (TTM) 2,67B
ROIC 4,34% FCF Growth (3Y) 12,36%
Safety
Debt / Equity 0,76 Current Ratio 1,11
Interest Coverage 4,21 Dividend Yield 0,04%
Valuation
P/E Ratio 33,73 P/B Ratio 2,23
P/S Ratio 2,59 PEG Ratio -29,05
EV/EBITDA 29,07 Dividend Yield 0,04%
Market Cap 56,60B Enterprise Value 74,93B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 21,84B 20,18B 19,37B 18,87B 19,13B
Net Income 1,68B 1,71B 1,48B 1,78B 2,09B
EPS (Diluted) 5,83 5,86 4,94 5,88 6,85
Gross Profit 9,92B 9,13B 8,17B 8,48B 8,63B
Operating Income 2,58B 2,40B 2,11B 2,28B 2,25B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 55,33B 57,29B 52,78B 52,93B 53,88B
Total Liabilities 29,94B 31,40B 26,98B 27,65B 30,20B
Shareholders' Equity 25,39B 25,89B 25,80B 25,28B 23,68B
Total Debt 19,18B 21,59B 16,82B 16,95B 18,42B
Cash & Equivalents 851,00M 1,86B 1,42B 1,16B 2,39B
Current Assets 9,26B 10,47B 8,68B 8,14B 8,84B
Current Liabilities 8,31B 8,96B 6,64B 7,81B 6,63B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#373 of 1024
51

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026